Tissue Regenix Group PLC First delivery of OrthoPure(R) XT (1941H)

TIDMTRX

RNS Number : 1941H

Tissue Regenix Group PLC

02 December 2020

Tissue Regenix Group plc

First delivery of OrthoPure(R) XT

Leeds, 2 December 2020 - Tissue Regenix Group (AIM:TRX) (the "Group"), the regenerative medical devices company, announces that its first delivery of OrthoPure(R) XT has taken place with additional shipments expected in early 2021.

OrthoPure(R) XT is a decellularized porcine tendon, developed using the Group's patented dCELL(R) technology. It was granted CE Mark approval in June 2020 for the reconstruction of knee ligaments to restore function and stability.

In August 2020, the Company announced its first distribution agreement, focused on the UK market, with a speciality supplier of orthopaedic and biologic products. The Group has since targeted key European markets including securing an additional distribution partner in Poland. The Group is currently engaged in a number of discussions with potential partners in other geographies.

Daniel Lee, Chief Executive Officer, Tissue Regenix Group, commented: "Our plan is to establish an initial distribution network for OrthoPure(R) XT and expand as procedural levels return. This will be a key product for the Group in Europe and highlights the need, and demand, for biologic solutions outside of the current US market. It is a testament to the work of our processing and commercial teams that we have secured distribution agreements and delivery of the product has remained on-track despite the challenges presented during 2020."

For more information:

 
 Tissue Regenix Group plc 
  Caitlin Pearson Head of Communications       Tel: [phone] 
------------------------------------------  --------------------- 
 
 Stifel Nicolaus Europe Limited (Nominated   Tel: [phone] 
  Adviser and Broker) 
  Ben Maddison / Alex Price 
------------------------------------------  --------------------- 
 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDFSWFAFESSEFE

(END) Dow Jones Newswires

December 02, 2020 02:00 ET (07:00 GMT)